Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Medica Hospitalia Indonesian Journal of Cancer
Yudadi, Redemptus
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Concomitant Colon Adenocarcinoma And Tuberculous Lymphadenitis Arya Abisatya, Albertus Magnus; Prameswari, Ajeng Andini; Fauzi, Agung Rahmat; Febrianto, Aji Pratama; Nugroho, Alexander Steven; Andisari, Hendrata Erry; Harijono, Pandu; Yudadi, Redemptus
Medica Hospitalia : Journal of Clinical Medicine Vol. 10 No. 3 (2023): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36408/mhjcm.v10i3.1007

Abstract

BACKGROUND : Colon involvement in tuberculosis infection is a rare event. The coexistence of colon carcinoma and tuberculous lesions of the colon is less frequently reported. Carcinoma and tuberculosis of the colon can occur at the same site or at different sites. The occurrence of two pathologies at the same site is much less common. CASE PRESENTATION : A 52 year old woman complained of difficulty defecating, an enlarged stomach, pain and decreased appetite and weight loss within one month. On clinical examination, the abdomen appeared convex, slightly distended, and tenderness in the left lower iliac quadrant. Radiological examination supported the diagnose of partial obstructive ileus. The patient was diagnosed with adenocarcinoma of the ascending colon until the hepatic flexura was confirmed through surgery and histopathological examination. On histopathological examination, adenocarcinoma of the colon was found to coexistence with tuberculous lymphadenitis of the colon. CONCLUSION : The etiological and pathophysiological relationship between tuberculous lymphadenitis and colon cancer is still under debate, but surgeons need to be aware of this occurrence, to choose treatment and avoid post-operative worsening.
Systemic Immune-Inflammation Index (SII) and NeutrophilLymphocyte Ratio (NLR) as a Promising Predictor for Advanced Stage Events during the Follow-Up Period in Hepato-Gastrointestinal Cancer Patients Zenjaya, Kellyn Trycia; Biutifasari, Verna; Yudadi, Redemptus; Wibowo, Prajogo
Indonesian Journal of Cancer Vol 18, No 4 (2024): December
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i4.1186

Abstract

Background: Tumor microenvironment has shown the role of inflammation in its progressivity. The heterogeneity of prognosis at the same TNM stage makes it difficult to classify patients who are more at risk of developing advanced stages. This study aimed to provide a deeper insight into the potential of cheap inflammation markers based on the Systemic ImmuneInflammation Index (SII) and Neutrophil-Lymphocyte Ratio (NLR) to predict the advanced stage during the follow-up period in patients with hepato-gastrointestinal cancer.Methods: Case-control research was conducted using 120 data of patients with hepatogastrointestinal cancer (Colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), esophageal adenocarcinoma (EAC), pancreatic ductal adenocarcinoma (PDAC), cholangio carcinoma (CCA)) taken from patient medical records. The patients were divided into case and control groups based on the presence of advanced stage events during the follow-up period that were further classified by the NLR and SII value. The advanced-stage events were analyzed and compared between the two groups using Chi-Square and logistic regression analysis to perceive the predictive value of each ratio. Results: Patients with advanced-stage hepato-gastrointestinal cancer had higher NLR and SII than patients without advanced stage (p 0.001). The group of patients with advanced stages had an average NLR of 18.45 and an SII of 6588.13. The group of patients without advanced stages had an average NLR of 5.12 and SII of 1545.01. The cut-off value was determined using the ROC curve, for NLR was 6.48 (92.5% sensitivity and 71.2% specificity), and for SII was 2264.24 (92.5% sensitivity and 76.2% specificity).Conclusions: NLR and SII are cheap markers and have considerable potential for predicting advanced stage during the follow-up period in patients with hepato-gastrointestinal cancer. SII is more accurate as a predictor than NLR. These tools can be very useful in identifying the high-risk patients among the same TNM stage.
Co-Authors Andisari, Hendrata Erry Arya Abisatya, Albertus Magnus Biutifasari, Verna Fauzi, Agung Rahmat Febrianto, Aji Pratama Harijono, Pandu Nugroho, Alexander Steven Prameswari, Ajeng Andini Wibowo, Prajogo Zenjaya, Kellyn Trycia